Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy

Gastroenterology and Hepatology

Volumn 10, Issue 6, 2014, Pages 355-363

  Lu, Ying ^a   Bousvaros, Athos ^b,c,d  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b Division of Pediatric Gastroenterology   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Crohn's disease; Immunization; Immunosuppression; Inflammatory bowel disease; Ulcerative colitis; Vaccine

Indexed keywords

CHICKENPOX VACCINE; CORTICOSTEROID; DIPHTHERIA PERTUSSIS TETANUS VACCINE; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; VIRUS VACCINE; WART VIRUS VACCINE;

CHILDHOOD DISEASE; DIPHTHERIA; DISEASE ACTIVITY; DISEASE SEVERITY; HAEMOPHILUS; HAND WASHING; HEPATITIS B VIRUS; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INFLUENZA; INFLUENZA VACCINATION; MAINTENANCE THERAPY; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; POLIOMYELITIS VIRUS; REVIEW; RISK FACTOR; SEROCONVERSION; TETANUS; VACCINATION; WART VIRUS;

EID: 84904251461     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411(6837):599-603. (Pubitemid 32531408)
2. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411(6837):603- 606. (Pubitemid 32531409)
3. Baldassano RN, Bradfield JP, Monos DS, et al. Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2007;5(8):972-976. (Pubitemid 47161140)
4. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461-1463. (Pubitemid 44871953)
5. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4807-4812. (Pubitemid 44323204)
6. Rufo PA, Bousvaros A. Current therapy of inflammatory bowel disease in children. Paediatr Drugs. 2006;8(5):279-302. (Pubitemid 44607534)
7. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104(10):2524-2533.
8. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53(pt 11):1155-1160. (Pubitemid 40052501)
9. Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96(7):2137-2142. (Pubitemid 32660910)
10. Posthuma EF, Westendorp RG, van der Sluys Veer A, Kluin-Nelemans JC, Kluin PM, Lamers CB. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut. 1995;36(2):311-313.
11. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53(9):1363-1365. (Pubitemid 39120128)
12. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12(6):974-976.
13. Zeitz J, Mullhaupt B, Fruehauf H, Rogler G, Vavricka SR. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology. 2009;50(2):653-654.
14. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008;43(5):397-401. (Pubitemid 351958904)
15. Deutsch DE, Olson AD, Kraker S, Dickinson CJ. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr. 1995;20(3):351-353.
16. Korelitz BI, Fuller SR, Warman JI, Goldberg MD. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am J Gastroenterol. 1999;94(2):424-426. (Pubitemid 29084663)
17. Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol. 2004;99(12):2503-2504. (Pubitemid 40039388)
18. Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2008;5(5):283-287. (Pubitemid 351637914)
19. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med. 2006;100(7):1291-1293. (Pubitemid 43793058)
20. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12(38):6167-6171. (Pubitemid 44688166)
21. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103(3):631-636. (Pubitemid 351405963)
22. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136(2):451-458.
23. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108(2):240-248.
24. Wasan SK, Coukos JA, Farraye FA. Vaccinating the inflammatory bowel disease patient: deficiencies in gastroenterologists knowledge. Inflamm Bowel Dis. 2011;17(12):2536-2540.
25. Narula N, Dhillon AS, Chauhan U, Marshall JK. An audit of influenza vaccination status in adults with inflammatory bowel disease. Can J Gastroenterol. 2012;26(9):593-596.
26. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101(8):1834-1840. (Pubitemid 44166594)
27. Crawford NW, Catto-Smith AG, Oliver MR, Cameron DJ, Buttery JP. An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2011;11(1):87.
28. Soon IS, deBruyn JC, Wrobel I. Immunization history of children with inflammatory bowel disease. Can J Gastroenterol. 2013;27(4):213-216.
29. Infectious Disease Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. http://www.idsociety. org/Templates/Content.aspx?id=32212256011. Accessed April 25, 2014.
30. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10(5):677-692. (Pubitemid 39276481)
31. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105(6):1231-1238.
32. American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:714-727.
33. Kopylov U, Levin A, Mendelson E, et al. Prior varicella zoster virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Aliment Pharmacol Ther. 2012;36(2):145-150.
34. Akinsanya-Beysolow I, Jenkins R, Meissner HC; ACIP Childhood/Adolescent Immunization Work Group; Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years - United States, 2013. MMWR Surveill Summ. 2013;62(suppl 1):2-8.
35. Radzikowski A, Banaszkiewicz A, Łazowska-Przeorek I, et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(5):1117-1124.
36. Urganci N, Kalyoncu D. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2013;56(4):412-415.
37. Park SH, Yang SK, Park SK, et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(1):69-74.
38. Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(12):1379-1385.
39. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460-1466.
40. Sempere L, Almenta I, Barrenengoa J, et al. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. Vaccine. 2013;31(30):3065-3071.
41. Altunöz ME, Senateş E, Yeşil A, Calhan T, Ovünç AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci. 2012;57(4):1039-1044.
42. Moses J, Alkhouri N, Shannon A, et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol. 2012;107(1):133-138.
43. Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Kinetics of anti-hepatitis B surface antigen titers after hepatitis B vaccination in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(3):554-558.
44. Brogan MD, Shanahan F, Oliver M, Stevens RH, Targan SR. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24(2):69-74. (Pubitemid 18040031)
45. Stevens R, Oliver M, Brogan M, Heiserodt J, Targan S. Defective generation of tetanus-specific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology. 1985;88(6):1860-1866. (Pubitemid 15052298)
46. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18(2):261-268.
47. Nielsen HJ, Mortensen T, Holten-Andersen M, Brünner N, Sørensen S, Rask-Madsen J. Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36(3):265-269. (Pubitemid 32234575)
48. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(1):148-154.
49. Lee CK, Kim HS, Ye BD, et al. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014;8(5):384-391.
50. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18(6):1042-1047.
51. Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441-1449.
52. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(7):851-856. (Pubitemid 47031059)
53. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):444-453.
54. deBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(1):25-33.
55. Cullen G, Bader C, Korzenik JR, Sands BE. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61(3):385-391.
56. Andrisani G, Frasca D, Romero M, et al. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis. 2013;7(4):301-307.
57. Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(6):759-762. (Pubitemid 46909992)
58. Naganuma M, Nagahori M, Fujii T, Morio J, Saito E, Watanabe M. Poor recall of prior exposure to varicella zoster, rubella, measles, or mumps in patients with IBD. Inflamm Bowel Dis. 2013;19(2):418-422.
59. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30, quiz CE2-CE4.
60. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2010;50(5):562-565.
61. Ansari F, Baker RD, Patel R, Baker SS. Varicella immunity in inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53(4):386-388.
62. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1-57.
63. Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40.